Sacramento, CANCT05423691Now EnrollingIRB Ready

Myelofibrosis Clinical Trial in Sacramento, CA

Access cutting-edge myelofibrosis treatment through this clinical trial at a research site in Sacramento. Study-provided care at no cost to qualified participants.

Sponsored by Cellenkos, Inc.

Quick Self-Assessment

See if you qualify for this Sacramento location

Preparing your pre-screening questions…

Expert Care in Sacramento

Access myelofibrosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related myelofibrosis treatment provided free

Apply for This Sacramento Location

Check if you qualify for this myelofibrosis clinical trial in Sacramento, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Sacramento

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Sacramento site if eligible
  4. 4Begin participation

About This Myelofibrosis Study in Sacramento

To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib

Sponsor: Cellenkos, Inc.

Who Can Participate

Inclusion Criteria

Ability to comprehend and willingness to sign a written informed consent form (ICF) for the study.
Age above 18 years inclusive at the time of signing the ICF.
Participants who fulfill the diagnostic criteria of myelofibrosis including primary myelofibrosis and myelofibrosis arising from polycythemia vera and essential thrombocythemia
Life expectancy is greater than 6 months.
Subject has been receiving ruxolitinib therapy, is unlikely to benefit from further ruxolitinib monotherapy in the opinion of the investigator; AND meeting the following criteria: receiving ruxolitinib \>3 months prior to enrollment; AND stable dose for 8 weeks before starting therapy with CK0804
Subject with evidence of evaluable residual burden of disease following ruxolitinib monotherapy treatment, consisting of:
presence of grade ≥2 anemia or thrombocytopenia or neutropenia, OR
presence of disease-related symptoms, as determined by a Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN SAF TSS) score of ≥10 points, OR
documented splenomegaly of at least 5 cm below the costal margin as measured by physical examination or splenomegaly as documented by ultrasound or MRI.
Willingness to avoid pregnancy or fathering children based on the criteria below
Men must agree to take appropriate precautions to avoid fathering children (with at least 99% certainty) from screening through 90 days after the last study treatment dose and must refrain from donating sperm during this period. Permitted methods that are at least 99% effective in preventing should be communicated to the participants and their understanding confirmed.
Women of childbearing potential must have a negative serum pregnancy test at screening before the first dose (within 3 days of the first study treatment dose) and must agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through the safety follow-up visit and must not donate oocytes during this period. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participants and their understanding confirmed,
Women of nonchildbearing potential (ie, surgically sterile with a hysterectomy and/or bilateral oophorectomy OR ≥ 12 months of amenorrhea and at least 50 years of age) are eligible.
ECOG performance status of 0 to 2

Exclusion Criteria

Any major surgery within 28 days before the first dose of study treatment.
Undergone any prior allogenic or autologous stem cell transplantation or a candidate for such transplantation.
Received chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy, biological therapy, endocrine therapy, targeted therapy, antibody or hypomethylating agent to treat the participant's disease, with the exception of ruxolitinib, within 5 half-lives or 28 days (whichever is shorter) before the first dose of study treatment.
Participant has received splenic irradiation within the past 6 months.
Significant concurrent, uncontrolled medical condition or infections, which in the opinion of the principal investigator may interfere in the study participation.
Inability or unlikeliness of the participant to comply with the dose schedule and study evaluations, in the opinion of the investigator.
Women who are pregnant or breastfeeding.
Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study treatment and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
Participants with laboratory values at screening as defined
Platelets \< 50 × 10\^9/L without the assistance of growth factors, thrombopoietic factors, or platelet transfusions
ANC \< 0.5 × 10\^9/L
ALT ≥ 2.5 × ULN
AST ≥ 2.5 × ULN
Direct Bilirubin \> 2.0 × ULN
ALP ≥ 3 × ULN
Creatinine clearance \< 50 mL/min according to Cockcroft-Gault formula.
Unwillingness to be transfused with blood components including RBC and platelet transfusions.
Inability of the participant (or parent, guardian, or legally authorized representative) to comprehend the ICF or unwillingness to sign the ICF.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Sacramento?

Yes, this clinical trial (NCT05423691) has an active research site in Sacramento, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Myelofibrosis Treatment Options in Sacramento, CA

If you're searching for myelofibrosis treatment options in Sacramento, CA, this clinical trial (NCT05423691) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Sacramento research site is actively enrolling participants for this clinical trial. You'll receive care from experienced myelofibrosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all myelofibrosis clinical trials near you to find additional studies recruiting in your area.

More Myeloproliferative Neoplasms Trials in Sacramento, CA

See all myeloproliferative neoplasms clinical trials recruiting in Sacramento — not just this study.

Browse Myeloproliferative Neoplasms Trials in Sacramento →

Browse More Trials by Condition

Myeloproliferative Neoplasms TrialsFibromyalgia TrialsMyelofibrosis TrialsAll Conditions →

Ready to Join in Sacramento?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Sacramento, CA